Pharmacokinetic and pharmacodynamic strategies to optimize antifungal therapy, prevent resistance and minimize treatment failure
JAC-Antimicrobial Resistance · 31.10.2026 · 8 (6)
DOI: 10.1093/jacamr/dlag231 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 04.11.2026. Verfasst von Norman Van Rhijn und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, University of Oxford, Oxford, UK. Die Arbeit nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mundipharma Research Limited.
Abstract (Originalsprache)
Invasive fungal diseases (IFDs) present significant challenges in clinical practice due to high morbidity and mortality rates, compounded by antifungal resistance, diagnostic limitations and pharmacokinetic (PK) and pharmacodynamic (PD) complexities. The main antifungal classes, triazoles, polyenes, echinocandins and pyrimidine analogues, are essential for managing IFDs but are increasingly undermined by resistance due to genetic mutations, efflux pump over-expression and biofilm formation. Some fungal pathogens, such as Candidozyma auris, can resist multiple antifungal classes by deploying a combination of mechanisms. PK/PD indices, including Cmax/minimum inhibitory concentration (MIC), AUC/MIC and percentage of time (%T) > MIC, are essential for optimizing antifungal therapy and improving the likelihood of adequate efficacy, while potentially limiting resistance selection through improved exposure. However, achieving these targets is often hindered by factors such as physiological variability, drug–drug interactions and inadequate tissue penetration, particularly in difficult-to-treat infections like fungal meningitis. Newer antifungal agents, including rezafungin, with its once-weekly dosing, and ibrexafungerp, the first-in-class oral triterpenoid, offer potentially useful additions to current therapy, although clinical experience and resistance-related outcome data remain limited for newer agents. These drugs feature enhanced PK/PD profiles and activity against resistant strains. Furthermore, therapeutic drug monitoring and advanced modelling techniques, such as Monte Carlo simulations, are vital for tailoring treatment regimens to individual patients. This review highlights the importance of integrating PK/PD principles, novel antifungal therapies and stewardship strategies to optimize antifungal exposure and support patient management in IFDs. These approaches may help reduce treatment failure and resistance selection, although direct clinical evidence for prevention of acquired resistance remains limited.
Autor:innen und Institutionen
- Department of Biology, University of Oxford, Oxford, UK.
- Public Health Wales (PHW) Mycology Reference Laboratory, University Hospital of Wales, Cardiff, UK.
- Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.
- Mycology Reference Centre Manchester, ECMM Centre of Excellence, and Department of Infectious Diseases, Manchester Academic Health Science Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manche…
- Division of Evolution, Infection and Genomics, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
ORCID-Profile: Riina Rautemaa-Richardson
Förderung
- Mundipharma Research Limited
Zitieren
APA
Van Rhijn, N., White, P. L., & Rautemaa-Richardson, R. (2026). Pharmacokinetic and pharmacodynamic strategies to optimize antifungal therapy, prevent resistance and minimize treatment failure. JAC-Antimicrobial Resistance, 8(6). https://doi.org/10.1093/jacamr/dlag231
Vancouver
Van Rhijn N, White PL, Rautemaa-Richardson R. Pharmacokinetic and pharmacodynamic strategies to optimize antifungal therapy, prevent resistance and minimize treatment failure. JAC-Antimicrobial Resistance. 2026;8(6). doi:10.1093/jacamr/dlag231
BibTeX
@article{VanRhijn2026,
author = {Van Rhijn, Norman and White, P Lewis and Rautemaa-Richardson, Riina},
title = {Pharmacokinetic and pharmacodynamic strategies to optimize antifungal therapy, prevent resistance and minimize treatment failure},
journal = {JAC-Antimicrobial Resistance},
year = {2026},
volume = {8},
number = {6},
doi = {10.1093/jacamr/dlag231}
}
EUVIMED